OP30: Lyophilised orally administered faecal microbiota transplantation for Active Ulcerative Colitis (LOTUS study)ECCO'21 VirtualYear: 2021
Authors: Haifer, C.(1);Saikal, A.(2);Paramsothy, S.(1);Borody, T.J.(3);Ghaly, S.(2);Kaakoush, N.O.(4);Leong, R.(1)
(1)The University of Sydney, Concord Clinical School, Sydney, Australia;(2)St Vincent's Hospital Sydney, Department of Gastroenterology and Hepatology, Sydney, Australia;(3)Centre for Digestive Diseases, Centre for Digestive Diseases, Sydney, Australia;(4)The University of New South Wales, Faculty of Medicine, Sydney, Australia
OP31: RESTORE: Interim analysis of a Phase 2 study of QBECO SSI for the induction and maintenance of clinical and endoscopic remission in subjects with Moderate to Severe Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Bressler, B.(1);Marshall, J.K.(2);Atkinson, K.(3);Sutcliffe, S.(4);Pankovich, J.(4);Jones, M.(4);Kalyan, S.(4);Gunn, H.(4)
(1)Gastrointestinal Research Institute, Vancouver, British Columbia, Canada;(2)McMaster University, Hamilton, Ontario, Canada;(3)Royal Columbian Hospital, New Westminster, British Columbia, Canada;(4)Qu Biologics Inc, Burnaby, British Columbia, Canada
OP32: Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn’s Disease patientsECCO'21 VirtualYear: 2021
Authors: Verburgt, C.(1,2);Dunn, K.(3);Bielawski, J.(3,4);Otley, A.(5);Heyman, M.(6);Sunseri, W.(7);Shouval, D.(8);Levine, A.(9);de Meij, T.(1);Hyams, J.(10);Denson, L.(11);Kugathasan, S.(12);Benninga, M.(1);de Jonge, W.(2,13);Van Limbergen, J.(1,2,5)
(1)Amsterdam University Medical Centers- Emma Children’s Hospital, Department of Paediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam, The Netherlands;(3)Dalhousie University, Department of Biology, Halifax, Canada;(4)Dalhousie University, Department of Mathematics & Statistics, Halifax, Canada;(5)Dalhousie University, Department of Paediatrics, Halifax, Canada;(6)University of California, UCSF Benioff Children’s Hospital and Department of Paediatrics, San Francisco, United States;(7)UPMC Children’s Hospital of Pittsburgh, Department of Pediatrics, Pittsburgh, United States;(8)Edmond and Lily Safra Children’s Hospital- Sheba Medical Center- Ramat Gan- Israel- Sackler Faculty of Medicine- Tel Aviv University, Pediatric Gastroenterology unit, Tel Aviv, Israel;(9)Wolfson Medical Center- Holon- Israel- Sackler School of Medicine- Tel Aviv University, Pediatric Gastroenterology and Nutrition Unit, Tel Aviv, Israel;(10)Connecticut Children’s Medical Center, Division of Digestive Diseases- Hepatology and Nutrition, Hartford, United States;(11)Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine, Department of pediatrics, Cincinatti, United States;(12)Emory University, Department of Pediatrics, Atlanta, United States;(13)University of Bonn, Department of Surgery, Bonn, Germany
OP33: Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella studyECCO'21 VirtualYear: 2021
Authors: Sandborn, W.(1);Danese, S.(2);Leszczyszyn, J.(3);Romatowski, J.(4);Altintas, E.(5);Peeva, E.(6);Vincent, M.(6);Reddy, P.(7);Banfield, C.(7);Banerjee, A.(7);Gale, J.(6);Hung, K.(6)
(1)University of California San Diego, Gastroenterology, La Jolla, United States;(2)Humanitas Research Hospital, Gastroenterology, Milan, Italy;(3)Melita Medical, Gastroenterology, Wroclaw, Poland;(4)Provincial Complex Hospital, Gastroenterology, Bialystok, Poland;(5)Mersin University, Gastroenterology, Mersin, Turkey;(6)Pfizer Inc., Inflammation and Immunology, Cambridge, United States;(7)Pfizer Inc., Early Clinical Development, Cambridge, United States
OP34: AJM300, an Oral Antagonist of α4-Integrin, as induction therapy for patients with Moderately Active Ulcerative Colitis: A Phase 3, randomized, double-blind, placebo-controlled induction studyECCO'21 VirtualYear: 2021
Authors: Watanabe, M.(1);Matsuoka, K.(2); Ohmori, T.(3);Nakajima, K.(4);Ishida, T.(5);Ishiguro , Y.(6);Kanke, K.(7);Kobayashi, K.(8);Hirai, F.(9);Watanabe, K.(10);Hibi, T.(11)
(1)Tokyo Medical and Dental University, Advanced Research Institute, Tokyo, Japan;(2)Toho University Sakura Medical Center, Department of Gastroenterology and Hematology, Chiba, Japan;(3)Ohmori Toshihide gastro-intestinal Clinic, Gastroenterology, Saitama, Japan;(4)Matsushima Clinic Yokohama Japan, Department of gastrointestinal division, Kanagawa, Japan;(5)Ishida Clinic of IBD and Gastroenterology, IBD and Gastroenterology, Oita, Japan;(6)National Hospital Organization Hirosaki National Hospital, Department of Gastroenterology and Hematology, Aomori, Japan;(7)Kanke Gastrointestinal Clinic, Gastrointestinal division, Tochigi, Japan;(8)Kitasato University School of Medicine, Research and Development Center for New Medical Frontiers, Kanagawa, Japan;(9)Fukuoka University Hospital, Department of Gastroenterology and Medicine, Fukuoka, Japan;(10)Hyogo College Of Medicine College Hospital, Department of Intestinal Inflammation Research, Hyogo, Japan;(11)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan
OP35: Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trialECCO'21 VirtualYear: 2021
Authors: Danese, S.(1);Vermeire, S.(2);D’Haens, G.(3);Panés, J.(4);Dignass, A.(5);Magro, F.(6,7);Nazar, M.(8);Le Bars, M.(9);Lahaye, M.(10);Ni, L.(11);Bravatà, I.(12);Gaya, D.R.(13);Peyrin-Biroulet, L.(14)
